Scinai Immunotherapeutics Ltd Total Assets
Scinai Immunotherapeutics Ltd total assets. Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) holds total assets worth $17.17 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Scinai Immunotherapeutics Ltd for the company's overall valuation and market capitalisation.
Total Assets of Scinai Immunotherapeutics Ltd (2000–2025)
Total assets of Scinai Immunotherapeutics Ltd from 2000 to 2025. This chart illustrates how Scinai Immunotherapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See SCNI live share price for real-time trading data and today's change.
Scinai Immunotherapeutics Ltd - Asset Composition Analysis
Scinai Immunotherapeutics Ltd Total Assets Breakdown (December 2025)
Scinai Immunotherapeutics Ltd total assets breakdown as of December 2025. Scinai Immunotherapeutics Ltd's total assets of $17.17 Million consist of 17.7% current assets and 82.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.3% |
| Accounts Receivable | $168.00K | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Scinai Immunotherapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Scinai Immunotherapeutics Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scinai Immunotherapeutics Ltd's current assets represent 17.7% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 14.3% of total assets in 2025, down from 100.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 1.5% of total assets.
Scinai Immunotherapeutics Ltd Competitors by Total Assets
Key competitors of Scinai Immunotherapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Scinai Immunotherapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.56 | 0.71 | 0.51 |
| Quick Ratio | 1.56 | 0.71 | 0.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.26 Million | $-614.00K | $-10.60 Million |
Scinai Immunotherapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Scinai Immunotherapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.22 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -13.5% |
| Total Assets | $11.63 Million |
| Market Capitalization | $319.75K USD |
Valuation Analysis
Below Book Valuation: The market values Scinai Immunotherapeutics Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scinai Immunotherapeutics Ltd's assets decreased by 13.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scinai Immunotherapeutics Ltd (2000–2025)
The table below shows the annual total assets of Scinai Immunotherapeutics Ltd from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $11.63 Million | -13.55% |
| 2024-12-31 | $13.45 Million | -23.03% |
| 2023-12-31 | $17.47 Million | -35.45% |
| 2022-12-31 | $27.07 Million | -15.51% |
| 2021-12-31 | $32.04 Million | +80.93% |
| 2020-12-31 | $17.71 Million | -47.17% |
| 2019-12-31 | $33.52 Million | +18.43% |
| 2018-12-31 | $28.30 Million | +20.54% |
| 2017-12-31 | $23.48 Million | +200.42% |
| 2016-12-31 | $7.82 Million | -26.28% |
| 2015-12-31 | $10.60 Million | +123.73% |
| 2014-12-31 | $4.74 Million | -36.37% |
| 2013-12-31 | $7.45 Million | +19.63% |
| 2012-12-31 | $6.22 Million | -13.10% |
| 2011-12-31 | $7.16 Million | -17.47% |
| 2010-12-31 | $8.68 Million | -3.02% |
| 2009-12-31 | $8.95 Million | +179.92% |
| 2008-12-31 | $3.20 Million | +440.12% |
| 2007-12-31 | $592.00K | -70.16% |
| 2006-12-31 | $1.98 Million | -40.69% |
| 2005-12-31 | $3.35 Million | -35.05% |
| 2004-12-31 | $5.15 Million | +110.63% |
| 2003-12-31 | $2.44 Million | +43.65% |
| 2002-12-31 | $1.70 Million | +170100.00% |
| 2001-12-31 | $1.00K | -66.67% |
| 2000-12-31 | $3.00K | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more